Successful intravenous foscarnet desensitization

Year 2022, Volume: 47 Issue: 4, 1787 - 1789, 28.12.2022

Özge Kangallı Boyacıoğlu , Suna Asilsoy , Serdar Al , Özge Atay

Abstract

Başarılı intravenöz foskarnet desentizasyonu

Abstract

Cmv is a life-threatening, opportunistic pathogen associated with significant morbidity and mortality in immunocompromised individuals. Citomegalovirus (cmv) retinitis is the most common ocular opportunistic complication and is a serious cause of vision loss in immunocompromised patients. Allergic drug reactions are unpredictable signs and symptoms that occur shortly (minutes to hours) after a particular drug is used at the appropriate dose. Allergic drug reactions can cause simple skin rashes or serious life-threatening anaphylactic or systemic reactions. However, desensitization is life-saving when there is no alternative medicine or when the patient's clinic is in question. Since our patient also had resistant cmv infection and we did not have an alternative drug, the drug had to be given by desensitizationto our knowledge, this is the first case of successful desensitization due to an early hypersensitivity reaction to foscarnet. Our result shows that desensitization to foscarnet is safe and effective in allergy.

Keywords

Pediatric, Desentisisation, Foscarnet, Cmv Retinitis

References

• 1. Vadlapudi ad, vadlapatla rk, mitra ak. Current and emerging antivirals for the treatment of cytomegalovirus (cmv) retinitis: an update on recent patents. Recent pat antiinfect drug discov. 2012;7(1):8-18. Doi:10.2174/157489112799829765
• 2. Cernadas jr, brockow k, romano a, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy. 2010;65(11):1357-1366. Doi:10.1111/j.1398-9995.2010.02441.x
• 3. Demoly p, adkinson nf, brockow k, et al. International consensus on drug allergy. Allergy. 2014;69(4):420-437. Doi:10.1111/all.12350
• 4. Caimmi s, caffarelli c, saretta f, et al. Drug desensitization in allergic children. Acta biomed. 2019;90(3-s):20-29. Published 2019 jan 28. Doi:10.23750/abm.v90i3-s.8158